Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis: a multicentre and retrospective study

To assess whether the retention rate of certolizumab pegol (CZP) was longer than that of other tumour necrosis factor inhibitors (TNFi) based on baseline rheumatoid factor (RF) levels. Longitudinal, retrospective and multicentre study including patients with RA who were treated with any TNFi (monocl...

ver descrição completa

Detalhes bibliográficos
Autores: López-Medina, Clementina, Calvo-Gutiérrez, Jerusalem, Ábalos-Aguilera, M Carmen, Cepas, Francisco, Plasencia-Rodríguez, Chamaida, Martínez-Feito, Ana, Balsa, Alejandro, Faré-García, Regina, Juan Mas, Antonio, Ruiz-Esquide, Virginia, Sainz, Luis, Díaz-Torné, César, Godoy-Navarrete, Francisco Javier, Añón-Oñate, Isabel, Mena-Vázquez, Natalia, Manrique-Arija, Sara, Moreno-García, Marina Soledad, Ortega-Castro, Rafaela, Escudero-Contreras, Alejandro
Tipo de documento: artigo
Data de publicação:2024
País:España
Recursos:Conselleria de Salut i Consum del Govern de les Illes Balears
Repositório:Docusalut
Idioma:inglês
OAI Identifier:oai:docusalut.com:20.500.13003/20276
Acesso em linha:https://hdl.handle.net/20.500.13003/20276
Access Level:Acceso aberto
Palavra-chave:Rheumatoid Factor
Tumor Necrosis Factor Inhibitors
Arthritis, Rheumatoid
Etanercept
Antibodies, Monoclonal
Treatment Outcome
Humans
Retrospective Studies
Certolizumab Pegol
Inhibidores del Factor de Necrosis Tumoral
Resultado del Tratamiento
Humanos
Factor Reumatoide
Estudios Retrospectivos
Anticuerpos Monoclonales
Artritis Reumatoide
id ES_7ca03bb66dc68fb49544a684e0f74841
oai_identifier_str oai:docusalut.com:20.500.13003/20276
network_acronym_str ES
network_name_str España
repository_id_str
spelling Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis: a multicentre and retrospective studyLópez-Medina, ClementinaCalvo-Gutiérrez, JerusalemÁbalos-Aguilera, M CarmenCepas, FranciscoPlasencia-Rodríguez, ChamaidaMartínez-Feito, AnaBalsa, AlejandroFaré-García, ReginaJuan Mas, AntonioRuiz-Esquide, VirginiaSainz, LuisDíaz-Torné, CésarGodoy-Navarrete, Francisco JavierAñón-Oñate, IsabelMena-Vázquez, NataliaManrique-Arija, SaraMoreno-García, Marina SoledadOrtega-Castro, RafaelaEscudero-Contreras, AlejandroRheumatoid FactorTumor Necrosis Factor InhibitorsArthritis, RheumatoidEtanerceptAntibodies, MonoclonalTreatment OutcomeHumansRetrospective StudiesCertolizumab PegolInhibidores del Factor de Necrosis TumoralResultado del TratamientoHumanosFactor ReumatoideEtanerceptEstudios RetrospectivosAnticuerpos MonoclonalesCertolizumab PegolArtritis ReumatoideTo assess whether the retention rate of certolizumab pegol (CZP) was longer than that of other tumour necrosis factor inhibitors (TNFi) based on baseline rheumatoid factor (RF) levels. Longitudinal, retrospective and multicentre study including patients with RA who were treated with any TNFi (monoclonal antibodies (mAB), etanercept (ETA) or CZP). Log-rank test and Cox regressions were conducted to evaluate the retention rate in the three groups according to the level of RF, with the third quartile of the baseline levels used as cut-off: <200 (<Q3) and ≥200 (≥Q3) IU/mL. A sensitivity analysis matching patients using a propensity score technique based on age, concomitant use of methotrexate and previous targeted synthetic/biological disease-modifying antirheumatic drugs was performed to address the imbalance across groups. A total of 638 individuals and 752 treatments (132 CZP, 439 mAB and 181 ETA) were included. In non-naïve patients with ≥200 IU/mL of RF, those treated with CZP showed a significantly longer retention rate in comparison with mAB and ETA. After matching using the propensity score, patients with ≥200 IU/mL RF levels exhibited longer retention rates with CZP than with mAB (HR 2.3 (95% CI 1.2 to 4.3), or ETA (HR 2.8 (95% CI 1.5 to 5.2). No differences were found between groups in patients with <200 UI/mL. CZP showed a longer retention rate than mAB and ETA in patients with very high RF levels (≥200 IU/mL), while these differences were absent in patients with <200 IU/mL levels. The results suggest the potential effect of RF on binding the fragment crystallisable portion of certain TNFi.BMJ20242024-02-2320242024-02-23research articlehttp://purl.org/coar/resource_type/c_2df8fbb1info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/20.500.13003/20276reponame:Docusalutinstname:Conselleria de Salut i Consum del Govern de les Illes BalearsInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Atribución 4.0 Internacionalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:docusalut.com:20.500.13003/202762026-06-22T12:44:07Z
dc.title.none.fl_str_mv Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis: a multicentre and retrospective study
title Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis: a multicentre and retrospective study
spellingShingle Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis: a multicentre and retrospective study
López-Medina, Clementina
Rheumatoid Factor
Tumor Necrosis Factor Inhibitors
Arthritis, Rheumatoid
Etanercept
Antibodies, Monoclonal
Treatment Outcome
Humans
Retrospective Studies
Certolizumab Pegol
Inhibidores del Factor de Necrosis Tumoral
Resultado del Tratamiento
Humanos
Factor Reumatoide
Etanercept
Estudios Retrospectivos
Anticuerpos Monoclonales
Certolizumab Pegol
Artritis Reumatoide
title_short Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis: a multicentre and retrospective study
title_full Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis: a multicentre and retrospective study
title_fullStr Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis: a multicentre and retrospective study
title_full_unstemmed Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis: a multicentre and retrospective study
title_sort Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis: a multicentre and retrospective study
dc.creator.none.fl_str_mv López-Medina, Clementina
Calvo-Gutiérrez, Jerusalem
Ábalos-Aguilera, M Carmen
Cepas, Francisco
Plasencia-Rodríguez, Chamaida
Martínez-Feito, Ana
Balsa, Alejandro
Faré-García, Regina
Juan Mas, Antonio
Ruiz-Esquide, Virginia
Sainz, Luis
Díaz-Torné, César
Godoy-Navarrete, Francisco Javier
Añón-Oñate, Isabel
Mena-Vázquez, Natalia
Manrique-Arija, Sara
Moreno-García, Marina Soledad
Ortega-Castro, Rafaela
Escudero-Contreras, Alejandro
author López-Medina, Clementina
author_facet López-Medina, Clementina
Calvo-Gutiérrez, Jerusalem
Ábalos-Aguilera, M Carmen
Cepas, Francisco
Plasencia-Rodríguez, Chamaida
Martínez-Feito, Ana
Balsa, Alejandro
Faré-García, Regina
Juan Mas, Antonio
Ruiz-Esquide, Virginia
Sainz, Luis
Díaz-Torné, César
Godoy-Navarrete, Francisco Javier
Añón-Oñate, Isabel
Mena-Vázquez, Natalia
Manrique-Arija, Sara
Moreno-García, Marina Soledad
Ortega-Castro, Rafaela
Escudero-Contreras, Alejandro
author_role author
author2 Calvo-Gutiérrez, Jerusalem
Ábalos-Aguilera, M Carmen
Cepas, Francisco
Plasencia-Rodríguez, Chamaida
Martínez-Feito, Ana
Balsa, Alejandro
Faré-García, Regina
Juan Mas, Antonio
Ruiz-Esquide, Virginia
Sainz, Luis
Díaz-Torné, César
Godoy-Navarrete, Francisco Javier
Añón-Oñate, Isabel
Mena-Vázquez, Natalia
Manrique-Arija, Sara
Moreno-García, Marina Soledad
Ortega-Castro, Rafaela
Escudero-Contreras, Alejandro
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv
dc.subject.none.fl_str_mv Rheumatoid Factor
Tumor Necrosis Factor Inhibitors
Arthritis, Rheumatoid
Etanercept
Antibodies, Monoclonal
Treatment Outcome
Humans
Retrospective Studies
Certolizumab Pegol
Inhibidores del Factor de Necrosis Tumoral
Resultado del Tratamiento
Humanos
Factor Reumatoide
Etanercept
Estudios Retrospectivos
Anticuerpos Monoclonales
Certolizumab Pegol
Artritis Reumatoide
topic Rheumatoid Factor
Tumor Necrosis Factor Inhibitors
Arthritis, Rheumatoid
Etanercept
Antibodies, Monoclonal
Treatment Outcome
Humans
Retrospective Studies
Certolizumab Pegol
Inhibidores del Factor de Necrosis Tumoral
Resultado del Tratamiento
Humanos
Factor Reumatoide
Etanercept
Estudios Retrospectivos
Anticuerpos Monoclonales
Certolizumab Pegol
Artritis Reumatoide
description To assess whether the retention rate of certolizumab pegol (CZP) was longer than that of other tumour necrosis factor inhibitors (TNFi) based on baseline rheumatoid factor (RF) levels. Longitudinal, retrospective and multicentre study including patients with RA who were treated with any TNFi (monoclonal antibodies (mAB), etanercept (ETA) or CZP). Log-rank test and Cox regressions were conducted to evaluate the retention rate in the three groups according to the level of RF, with the third quartile of the baseline levels used as cut-off: <200 (<Q3) and ≥200 (≥Q3) IU/mL. A sensitivity analysis matching patients using a propensity score technique based on age, concomitant use of methotrexate and previous targeted synthetic/biological disease-modifying antirheumatic drugs was performed to address the imbalance across groups. A total of 638 individuals and 752 treatments (132 CZP, 439 mAB and 181 ETA) were included. In non-naïve patients with ≥200 IU/mL of RF, those treated with CZP showed a significantly longer retention rate in comparison with mAB and ETA. After matching using the propensity score, patients with ≥200 IU/mL RF levels exhibited longer retention rates with CZP than with mAB (HR 2.3 (95% CI 1.2 to 4.3), or ETA (HR 2.8 (95% CI 1.5 to 5.2). No differences were found between groups in patients with <200 UI/mL. CZP showed a longer retention rate than mAB and ETA in patients with very high RF levels (≥200 IU/mL), while these differences were absent in patients with <200 IU/mL levels. The results suggest the potential effect of RF on binding the fragment crystallisable portion of certain TNFi.
publishDate 2024
dc.date.none.fl_str_mv 2024
2024-02-23
2024
2024-02-23
dc.type.none.fl_str_mv research article
http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/20.500.13003/20276
url https://hdl.handle.net/20.500.13003/20276
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Atribución 4.0 Internacional
http://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Atribución 4.0 Internacional
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv BMJ
publisher.none.fl_str_mv BMJ
dc.source.none.fl_str_mv reponame:Docusalut
instname:Conselleria de Salut i Consum del Govern de les Illes Balears
instname_str Conselleria de Salut i Consum del Govern de les Illes Balears
reponame_str Docusalut
collection Docusalut
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869411604735459328
score 15,811543

Registros relacionados